Skip to main content
CRMD logo

CRMD · CorMedix Inc.

Track CRMD — free
$4.96 +0.46 (+10.22%)
Market Cap
$357.92M
Shares
79.54M
Volume · Nov 19 1.23M Avg daily vol (3M) 1.37M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.50 Open$4.65 Day$4.49–4.71 52W close$4.50–12.73 Avg vol 30d1.9M Short int14.2M · 17.9% of shares · 8.4d Short vol54% Last earningsNov 12, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 12

Up next

Mar 4, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 16
Proxy statement DEFA14A
Revenue reaches $54.5 million; 2026 guidance narrowed

CorMedix reported third-quarter revenue of $54.5 million, adjusted EBITDA of $3.1 million and $355 million cash. It maintained 2026 revenue guidance of $325 million to $345 million and narrowed adjusted EBITDA guidance to $130 million to $140 million.

2 source passages
For the third quarter, we reported consolidated revenue of $54.5 million, above consensus and adjusted EBITDA of $3.1 million, and we ended the quarter with $355 million in cash. Last week, we reaffirmed our full year 2026 revenue guidance with a range of $325 million to $345 million. And today, we’re also narrowing our full year adjusted EBITDA guidance to the top end of the previous range to $130 million to $140 million. Open the document at this passage
Nov 16
Current report 8-K Events of Nov 12
Heron Therapeutics acquisition expected to close in first quarter 2027

CorMedix expects its proposed acquisition of substantially all Heron Therapeutics assets to close in the first quarter of 2027. Third-quarter revenue was $54.5 million and adjusted EBITDA was $3.1 million; 2026 revenue guidance remained $325 million to $345 million.

Regulation FD disclosure
4 source passages
In addition, today’s discussion includes statements regarding CorMedix’s proposed acquisition of substantially all the assets of Heron Therapeutics, which remains subject to approval by Heron’s stockholders, regulatory clearance and other customary closing conditions. We expect the transaction to be immediately accretive to earnings and free cash flow upon closing, which we anticipate in the first quarter of 2027, subject to Heron stockholder approval, regulatory clearance and other customary closing conditions. For the third quarter, we reported consolidated revenue of $54.5 million, above consensus and adjusted EBITDA of $3.1 million, and we ended the quarter with $355 million in cash. As discussed earlier, we are maintaining our full year 2026 consolidated revenue guidance of $325 million to $345 million, and we are narrowing our adjusted EBITDA guidance to $130 million to $140 million, the high end of our previous range. Open the document at this passage
Nov 12
Earnings call
Heron Therapeutics acquisition targets revenue and cost synergies

CorMedix Inc. expects to close its acquisition of substantially all Heron Therapeutics assets in the first quarter of 2027, targeting $125 to $150 million of revenue in 2027 and $45 to $60 million of annualized operating cost synergies.

4 source passages
On Monday, we announced the definitive agreement to acquire substantially all the assets of Heron Therapeutics, encompassing both commercial and pipeline assets that we believe are highly complementary and synergistic with Cormetic's growth strategy in institutional settings of care. we expect the acquired products to contribute approximately $125 to $150 million of revenue for Proforma 2027. which supports the $45 to $60 million in estimated operating cost synergies that we expect to achieve on an annualized run rate basis by the end of 2027. We expect the transaction to be immediately accreted to earnings and free cash flow upon closing, which we anticipate in the first quarter of 2027. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Heron deal: four products for $145.0 million cash, 14,583,333 shares

CorMedix agreed to acquire substantially all of Heron Therapeutics’ assets, adding four commercial-stage products—ZYNRELEF, APONVIE, CINVANTI and SUSTOL—for $145.0 million cash and 14,583,333 shares. Closing is expected in the first quarter of 2027.

Revenue $54.52M ▼ 47.7% Net loss $14.72M Diluted EPS -$0.19
Read from the MD&A section
3 source passages
On November 8, 2026, we entered into an asset purchase agreement (the "Agreement") with Heron Therapeutics, Inc. ("heron"), pursuant to which Heron has agreed to sell substantially all of its assets, other than certain excluded assets, to us, and we have agreed to acquire those assets and assume certain liabilities of Heron as set forth in the Agreement (the "Acquisition"). If consummated, the Acquisition would add four commercial-stage products to our portfolio: ZYNRELEF (bupivacaine and meloxicam) extended-release solution for postoperative pain; APONVIE (aprepitant) injectable emulsion for the prevention of postoperative nausea and vomiting; CINVANTI (aprepitant) injectable emulsion and SUSTOL (granisetron) extended-release injection for the prevention of chemotherapy-induced nausea and vomiting. Under the terms of the Agreement, we will pay upfront consideration at the closing of the Acquisition consisting of $145.0 million in cash, subject to certain adjustments for Heron's closing cash and net working capital, of which $2.0 million will be deposited into escrow at closing to secure post-closing adjustments (which may not exceed $10.0 million in either direction), and to issue 14,583,333 shares of CorMedix common stock. The Acquisition is not subject to any financing contingency and is expected to close in the first quarter of 2027. Open the document at this passage
Nov 12
Current report 8-K
Third-quarter revenue totals $54.5 million

CorMedix reported third-quarter revenue of $54.5 million, net loss of $14.7 million and adjusted EBITDA of $3.1 million. For its pending Heron asset acquisition, a term loan provides up to $150 million, with $75 million expected at closing.

Financial results
3 source passages
CorMedix announces $54.5 million of total revenue and grant income ("consolidated revenue") for the third quarter of 2026, above street consensus of $51.2 million, reflecting steady third quarter execution in the face of post-TDAPA headwinds for DefenCath. The Company also recognized a net loss of $14.7 million and adjusted EBITDA of $3.1 million (1). CorMedix and Heron Therapeutics, Inc. ("Heron") announced on November 9, 2026, that they have entered into a definitive asset purchase agreement under which CorMedix will acquire substantially all of the assets of Heron. In connection with the Heron asset acquisition, CorMedix entered into a term loan agreement to provide up to $150 million in non-dilutive capital, of which the Company expects to utilize $75 million upon closing. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$412.49M
Trailing 12 months
Net income (TTM)
$63.89M
Trailing 12 months
Revenue growth YoY
-47.7%
Year over year
Operating margin
38.6%
Trailing 12 months
P / E (TTM)
6.2
Trailing earnings · reciprocal yield 16.2%
FCF yield
86.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$355.15M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-9.0%
Year over year · fewer shares
Price change (1Y)
-55.4%
Trailing year
Short interest
17.9%
Latest settlement · 8.4 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 12, 2026
Q3 FY26

TL;DR. Bullish, management expects the 2027 DefenCath add-on to exceed $2.37 each quarter, Heron to add approximately $125 to $150 million of pro forma revenue and generate $45 to $60 million of synergies, and reported Q3 revenue above consensus alongside $355 million of cash; 2026 guidance was reaffirmed and Rezeo received priority FDA review. Bearish, average 2027 DefenCath reimbursement is expected below $8.32, 2027 DefenCath guidance is deferred, TPN enrollment is behind schedule, and Medicare Advantage contracting, LDO pilot orders and Azzerty litigation and competition remain unresolved risks.

Bullish
  • + The DefenCath add-on is expected to exceed $2.37 in every quarter of 2027, with an average at least double the current rate.
  • + The acquired Heron products are expected to contribute approximately $125 to $150 million of pro forma 2027 revenue, roughly doubling the non-DefenCath revenue base.
  • + Management reaffirmed 2026 revenue guidance of $325 to $345 million and narrowed adjusted EBITDA guidance to $130 to $140 million.
  • + Third-quarter revenue was $54.5 million and above consensus, with adjusted EBITDA of $3.1 million and $355 million of cash.
  • + The Rezeo prophylaxis application was accepted for FDA review with priority review status and a target action date in the first quarter of 2027.
  • + The Heron transaction is expected to generate $45 to $60 million of annualized operating cost synergies by the end of 2027.
Bearish
  • − Average 2027 reimbursement for DefenCath is expected to be lower than $8.32 over the course of the year.
  • − The Phase III TPN study enrollment is tracking meaningfully behind the original timetable.
  • − The Medicare Advantage contractual framework was not largely final, and operationalization hurdles remained.
  • − The LDO pilot had not generated repeat orders.
  • − The Heron revenue range is exposed to the Azzerty litigation and the risk of a competing branded launch.
  • − Management deferred 2027 DefenCath guidance pending visibility into pricing, utilization and Medicare Advantage upside.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −40%
below
Price vs 50-day avg −35%
below
RSI (14) 25
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −42%
trailing
6-month return −47%
trailing
YTD return −61%
this year
Relative strength −43%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $7 › 200d $8 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +22 funds added
Insider flow Accumulating
Net +$513.2K over 90 days · 0% sells
Short interest Falling
17.86% of shares out · ▼ -3.1% MoM · 8.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
191 holders — mid 3-yr range
Squeeze score 74
high risk · 0–100
Fundamentals
Excellent
Revenue growth +617%
Y/Y
Gross margin 88%
contracting
EPS growth +780%
Y/Y
Free cash flow $172.8M
Buyback $75.0M
authorized
Quant / Vol
risk profile
Very High
Volatility 64%
annualized · 1-yr
Max drawdown −65%
past year
ATR 8.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 12, 2026
full year 2026
Revenue Maintained $325M – $345M
Nov 2, 2026 $325M – $345M changed to Nov 12, 2026 $325M – $345M
prior FY $311.71M midpoint +7.5% Y/Y
full-year 2026
Adjusted EBITDA Non-GAAP Raised $130M – $140M
Aug 13, 2026 $125M – $140M changed to Nov 12, 2026 $130M – $140M
Proforma 2027
Revenue for acquired products $125M – $150M
annualized run rate basis by the end of 2027
Estimated operating cost synergies $45M – $60M
Previous outlook earlier release · from the 8-K filed Nov 2, 2026

Still-open targets the latest release did not restate under the same label.

Add-on rate for all four quarters in 2027 · all four quarters in 2027 at least $2
Guided vs delivered · last 1 settled
Net revenue fourth quarter
guided $115M – $135M
$128.62M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−40% Bearish
Price vs 50-day avg
−35% Bearish
RSI (14)
25 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $8 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +22 funds added
Insider flow Accumulating
Net +$513.2K over 90 days · 0% sells
Short interest Falling
17.86% of shares out · ▼ -3.1% MoM · 8.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
191 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5 Now $5 · 0% Range high $13
vs 200-day avg -40% vs 50-day avg -35%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA (Non-GAAP) non-GAAP $131.87M For the Nine Months Ended September 30, 2026 —
DefenCath $17,181 the three months ended September 30, 2026 filing —
EBITDA (Non-GAAP) non-GAAP $109.21M For the Nine Months Ended September 30, 2026 —
Melinta Portfolio $31,441 the three months ended September 30, 2026 filing —
sales of DefenCath 17.2M third quarter of 2026 —
Shares of common stock sold under the 2024 ATM program 1.3M the three months ended September 30, 2026 filing —
Melinta portfolio net revenue $35.8M the second quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CRMD
CorMedix Inc.
this stock
$357.92M -61.3% +617.0% — 17.9%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
191
% held
58.6%
Net QoQ
+2.6M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
147
View
Short & Settlement
Short Interest Falling
Shares short
14.2M
Days to cover
8.4d
Change
-459.7K sh
View
Short Volume
Short vol %
54%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
13.4K
Value
$110.1K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
43.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$513.2K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$311.7M
Net income (FY)
$163.1M
EPS diluted
$2.04
View
Buybacks
Authorized
$75.0M
View
Filings
SEC Filings
Latest
DEFA14A
Filed
Nov 16, 2026
This year
29

CorMedix reported third-quarter revenue of $54.5 million, adjusted EBITDA of $3.1 million and $355 million cash. It maintained 2026 revenue guidance of $325 million to $345 million and narrowed adjusted EBITDA guidance to $130 million to $140 million.

View
Proposed Sales
Value
$68.5K
Shares
10.0K
Filed
Jan 21, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Cormedix Therapeutics Reports Thi…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
CRMD -15.1% -42.2% -46.7% -21.0% -61.3%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -11.2% -36.7% -43.2% -17.6% -68.4%

Capital returns

Buyback program · as of Feb 2, 2026
Authorized
$75.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1410098 CUSIP 21900C308 13F (30d) 201 filings 183 filers Visit website Investor relations